Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phagyo Spray is a polyvalent bacteriophage preparation developed by Biochimpharm for the treatment and prevention of bacterial infections. It contains a cocktail of specific bacteriophages that target and lyse common pathogenic bacteria, including *Staphylococcus*, *Streptococcus*, *Escherichia coli*, *Pseudomonas aeruginosa*, and *Proteus*. The product is designed for topical and mucosal application, particularly for throat infections, oral cavity diseases, surgical wounds, and burns. As a phage therapy, it offers a targeted approach to bacterial eradication, potentially bypassing antibiotic resistance mechanisms by utilizing the natural predatory cycle of viruses that infect bacteria. The product is currently approved and marketed in Georgia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Phagyo Spray.